Differential Involvement of 5-HT1B/1D and 5-HT6 Receptors in Cognitive and Non-cognitive Symptoms in Alzheimer's Disease

Neuropsychopharmacology

Volumn 29, Issue 2, 2004, Pages 410-416

  Garcia Alloza, M ^a   Hirst, W D ^b   Chen, C P L H ^c   Lasheras, B ^a   Francis, P T ^d   Ramirez M J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b GLAXOSMITHKLINE   (United Kingdom)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acetylcholine; Behavioral and psychological syndromes of dementia (BPSD); Mini Mental State Examination (MMSE); Post mortem studies; Present Behavioral Examination (PBE); Serotonin

Indexed keywords

CHOLINE ACETYLTRANSFERASE; RECEPTOR BLOCKING AGENT; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 6 RECEPTOR;

AGED; AGGRESSION; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BEHAVIOR; BRAIN CORTEX; CADAVER; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; MEMORY DISORDER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY; SEROTONINERGIC SYSTEM; SYMPTOMATOLOGY; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BENZAMIDES; BINDING SITES; CHOLINE O-ACETYLTRANSFERASE; COGNITION DISORDERS; FEMALE; FRONTAL LOBE; HUMANS; ISOTOPES; MALE; MEMORY DISORDERS; MENTAL STATUS SCHEDULE; NEUROPSYCHOLOGICAL TESTS; PIPERAZINES; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; STATISTICS; SULFONAMIDES; TEMPORAL LOBE;

EID: 0842308152     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300330     Document Type: Article

References (78)

1. American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders III-R ed. APA: Washington DC.
2. Bahn S, Augood SJ, Ryan M, Standaert DG, Starkey M, Emson PC (2001). Gene expression profiling in the post-mortem human brain - no cause for dismay. J Chem Neuroanat 22: 79-94.
3. 3 receptor recognition sites in Alzheimer's disease. NeuroReport 1: 253-254.
4. Barnes NM, Sharp T (1999). A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083-1152.
5. Bentley JC, Bourson A, Boess FG, Fone KC, Marsden CA, Petit N et al (1999). Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats. Br J Pharmacol 126: 1537-1542.
6. Berman ME (1997). The serotonin hypothesis of aggression revisited. Clin Psychol Rev 17: 651-665.
7. Bourson A, Borroni E, Austin RH, Monsma Jr FJ, Sleight AJ (1995). Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides. J Pharmacol Exp Ther 274: 173-180.
8. Bradford MM (1976). A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
9. Branchek TA, Blackburn TP (2000). 5-ht6 receptors as emerging targets for drug discovery. Ann Rev Pharmacol Toxicol 40: 319-334.
10. Buhot MC (1997). Serotonin receptors in cognitive behaviors. Curr Opin Neurobiol 7: 243-254.
11. Buhot MC, Martin S, Segu L (2000). Role of serotonin in memory impairment. Ann Med 32: 210-221.
12. 3H]acetylcholine release in hippocampal grafts of septal origin. Brain Res 704: 153-156.
13. Chen CPLH, Alder JT, Bowen DM (1996). Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J Neurochem 66: 1592-1598.
14. Chen CPLH, Eastwood SL, Hope T, McDonald B, Francis PT, Esiri MM (2000). Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. Neuropath App Neurobiol 26: 1-10.
15. Chen CHLH, Hope R, Alder JT, Eastwood S, Gedling K, McDonald B et al (1995). Loss of paroxetine binding in the neocortex is associated with depression in Alzheimer's disease. In: Iqbal K, Mortimer J, Winbad B, Wisnieski H (eds) Research Advances in Alzheimer's Disease and Related Disorders. John Wiley & Sons Ltd: New York, pp 467-473.
16. 2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. J Neurol Sci 106: 50-55.
17. Cross AJ (1990). Serotonin in Alzheimer-type dementia and other dementing illnesses. Ann N Y Acad Sci 600: 405-415.
18. Curcio CA, Kemper T (1984). Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol 43: 359-368.
19. Davidson C, Stanford J (1995). Evidence that 5-hydroxytryptamine release in rat dorsal raphe nucleus is controlled by 5-HT1A, 5-HT1B and 5-HT1D autoreceptors. Br J Pharmacol 114: 1107-1109.
20. 6 receptor antagonist SB-270146 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br J Pharmacol 130: 23-26.
21. 6 receptor antagonist SB-270146 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25: 662-668.
22. 6 receptor antagonist. Brain Res Bull 59: 513-521.
23. 3H]-GR-125743, a novel radiolabelled serotonin 5-HT1D/1B receptor antagonist. Naunyn-Schmiedderberg's Arch Pharamacol 356: 328-334.
24. Esiri MM (1996). The basis for behavioural disturbances in dementia. J Neurol Neurosurg Psychiatry 61: 127-130.
25. Folstein MF, Folstein S, McHugh PR (1975). Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
26. Fone CF (2000). The 5-HT6 receptor: potential CNS functions. Br J Pharmacol 131: 238P.
27. Fonnun F (1975). A rapid radiochemical method for the determination of choline acetyltransferase. J Neurochem 24: 407-409.
28. Forstl H, Burns A, Levy R, Cairns N (1994). Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease. Br J Psychiatry 165: 53-59.
29. Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CPLH, Francis PT, Lasheras B et al Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease (submitted).
30. 6 receptor-like material in the rat central nervous system. Brain Res 746: 207-219.
31. Gottfries CG (1990). Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia. J Neural Transm 30: 33-43.
32. Hamon M, Doucet E, Lefevre K, Miquel MC, Lanfumey L, Insausti R et al (1999). Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptos. Neuropsychopharmacology 21: 68S-76S.
33. 6 receptors in rat, pig and human brain tissue. Br J Pharmacol 130: 1597-1605.
34. Hope T, Fairburn CG (1992). The present behavioural examination (PBE): the development of an interview to measure current behavioural abnormalities. Psychol Med 22: 223-230.
35. Hope T, Keene J, Fairburn C, McShane R, Jacoby R (1997). Behavior changes in dementia 1: point of entry data of a prospective study. Int J Geriat Psychiatry 12: 1062-1073.
36. IPA (1996). Behavioral and psychological signs and symptoms in dementia (BPSSD): implications for research and treatment. Int Psychogeriatr 8: 215-552.
37. Johnson SW, Mercuri NB, North RA (1992). 5-Hydroxytryptaminelb receptors block the GABAB synaptic potential in rat dopamine neurons. J Neurosci 12: 2000-2006.
38. Jones BJ, Blackburn TP (2002). The medical benefit of 5-HT research. Pharmacol Biochem Behav 71: 555-568.
39. Keene J, Hope T, Fairburn C, Jacoby R, Gedling K, Ware C (1999). The natural history of aggressive behaviour in dementia. Int J Geriat Psychiatry 14: 541-548.
40. Lai MKP, Lai OF, Keene J, Esiri MM, Francis PT, Hope T et al (2001). Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex. Neurology 57: 805-811.
41. Lai MKP, Tsang SWY, Francis PT, Keene J, Hope T, Esiri MM et al (2002). Post-mortem serotonergic correlates of cognitive decline in Alzheimer's disease. NeuroReport 13: 1175-1178.
42. Levy ML, Cummings JL, Kahn-Rose R (1999). Neuropsychiatric symptoms and cholinergic therapy for Alzheime's disease. Gerontology 45: 15-22.
43. Lewis DA (2002). The human brain revisited: opportunities and challenges in post-mortem studies of psychiatric disorders. Neuropsychopharmacology 26: 143-154.
44. Linnoila VMI, Virkkunen M (1992). Aggression, suicidality and serotonin. J Clin Psychiatry 53: 46-51.
45. Martinson IM, Muwaswes J, Gilliss CL, Doyle GD, Zimmerman S (1995). The frequency and troublesomeness of syndromes associated with Alzheimer's disease. J Community Health Nurs 12: 47-57.
46. 1B receptor mediating inhibition of acetylcholine release. Eur J Neurosci 129: 333-337.
47. McKhann G, Drachman D, Folstein MF, Katzman R, Price D, Stadlan EM (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944.
48. Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY et al (1998). Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 18: 407-430.
49. 1B receptor inverse agonism affect learning consolidation? Neurosci Biobehv Rev 25: 193-201.
50. 2C receptors in learning. Behav Brain Res 87: 105-110.
51. 2A) in the consolidation of learning. Behav Brain Res 89: 217-223.
52. Miguel-Hidalgo J (2001). SB-271046. Curr Opin Invest Drugs 2: 118-122.
53. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al (1991). The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standarization of neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486.
54. Nazarali AJ, Reynolds GP (1992). Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study. Cell Mol Neurobiol 12: 581-587.
55. 6 receptors in rat nucleus accumbens by antisense oligonucleotides. Neuroscience 92: 1001-1009.
56. 3H]8-OH-DPAT binding in Alzheimer's disease: an index of pyramidal cell loss?. In: Dourish C, Ahlenius A, Hutson P (eds.) Brain 5-HT1A Receptors. Ellis Howood Ltd., Chichester. pp 286-299.
57. Palmer AM, Wilcock GK, Esiri MM, Francis PT, Bowen DM (1987b). Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease. Brain Res 20: 231-238.
58. Parnetti L, Amici S, Lanari A, Gallai V (2001). Pharmacological treatment of non-cognitive disturbances in dementia disorders. Mech Ageing Develop 122: 2063-2069.
59. Perry EK, Johnson M, Kerwin JM, Piggot MA, Court JA, Shaw PJ et al (1992). Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol Aging 13: 393-400.
60. Perry EK, Walker M, Grace J, Perry R (1999). Acetylcholine in mind: a neurotransmitter correlate of consciousness? TINS 22: 273-280.
61. Procter AW, Francis PT, Stratmann GC, Bowen DM (1992). Serotonergic pathology is not widespread in Alzheimer patients without prominent aggresive symptoms. Neurochem Res 17: 917-922.
62. Raiteri M, Marchi M, Maura G, Bonanno G (1989). Presynaptic regulation of acetylcholine release in the CNS. Cell Biol Int Rep 13: 1109-1118.
63. 6 receptor antagonists. Curr Opin Invest Drugs 2: 104-109.
64. 6 receptor antagonist. J Med Chem 46: 1273-1276.
65. 6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology 158: 114-119.
66. Roth M, Tym E, Montjoy CQ, Huppert FA, Hendrie H, Verma S et al (1986). CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149: 698-709.
67. 1B auto and heteroreceptors. Naunyn-Schmiedeberg's Arch Pharmacol 360: 382-390.
68. Sarter M, Bruno JP (1997). Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Rev 23: 28-46.
69. Shirazi-Southall S, Rodriguez DE, Nomikos GG (2002). Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26: 583-594.
70. 7 serotonin receptors: molecular biology, functional correlates and possible therapeutic indications. Drugs News Perspect 10: 214-224.
71. Sparks DL, Hunsaker JC, Slevin JT, DeKosky ST, Kryscio RJ, Markesbery WR (1992). Monoaminergic and cholinergic synaptic markers in the nucleus basalis of Meynert (nbM): normal age-related changes and the effect of heart disease and Alzheimer's disease. Ann Neurol 31: 611-620.
72. Sweet RA, Hamilton RL, Lopez OL, Klunk WE, Wisniewski SR, Kaufer DI et al (2000). Psychotic symptoms in Alzheimer's disease are not associated with more severe neuropathologic features. Int Psychogeriatr 12: 547-558.
73. 6 receptor null mutant mice. IUPHAR Satellite Meet on Serotonin. Rotterdam (Abstract) S1-S2.
74. 6 with neuropeptides in rat striatum. J Comp Neurol 370: 405-414.
75. Wolff M, Savova M, Malleret G, Hen R, Segu L, Buhot MC (2003). Serotonin IB knockout mice exhibit a task-dependent selective learning facilitation. Neurosci Lett 338: 1-4.
76. 6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 41: 210-219.
77. 6 receptor antagonist, Ro-046790, in rats. Br J Pharmacol 129: 64.
78. Zubenko GS, Moossy J, Martinez J, Rao G, Claassen K, Rosen J et al (1991). Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 48: 619-624.